ArticleFrontiers in immunology2026
Impact of dose-adjusted tacrolimus exposure phenotype on outcomes in kidney transplantation: a large-scale multicenter cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Dose-adjusted tacrolimus exposure phenotype, expressed as the trough concentration-to-dose ratio (C0/Dose), may influence post-transplant outcomes, but supporting evidence remains limited. Methods: We evaluated the association between tacrolimus exposure phenotype and short- and long-term allograft and patient outcomes in a multicenter retrospective cohort study using clinical data warehouse records from five tertiary transplant centers in South Korea (2005-2020). Patients were classified into fast- or slow-dose-adjusted exposure phenotypes using trajectory clustering. Primary outcomes included 1-year endpoints (graft failure, biopsy-proven acute rejection, Results: Among 5,965 recipients, 4,595 (77.0%) were classified as fast-exposure phenotype and 1,370 (23.0%) as slow-exposure phenotypes. Slow-exposure phenotypes received lower tacrolimus doses (time-weighted median 2.1 vs 4.6 mg/day, P < 0.001) but had higher trough levels (6.7 vs 6.1 ng/mL, P < 0.001), higher variability (27.8 vs 26.4%, P < 0.001), and greater time above the therapeutic range (19.7 vs 11.6%, P < 0.001). After IPTW, 1-year efficacy outcomes (biopsy-proven acute rejection, graft failure, and de novo donor-specific antibody development) did not differ significantly between groups. During years 2-6, slow-exposure phenotypes had higher risks of all-cause mortality (adjusted HR 1.616, 95% CI, 1.069-2.442), serious infection requiring hospitalization (adjusted HR 1.537, 95% CI, 1.166-2.026), and malignancy (adjusted HR 1.628, 95% CI, 1.077-2.460). Discussion: A slow tacrolimus exposure phenotype (high C0/Dose) may serve as a risk marker of cumulative overexposure, associated with increased late mortality, serious infection, and malignancy. Phenotype-informed longitudinal exposure monitoring may improve long-term risk stratification, although whether targeted dose adjustment improves outcomes requires prospective interventional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.